AstraZeneca will present data across its COVID-19 and respiratory syncytial virus (RSV) pipeline at the 10th Annual IDWeek Virtual Conference, 29 September to 3 October 2021, illustrating its commitment to advancing innovative science in infectious diseases.
Data featuring AstraZeneca’s investigational long-acting antibody (LAAB) programmes – AZD7442 for COVID-19 and nirsevimab for RSV – as well as its COVID-19 vaccine Vaxzevria, will be presented as three late-breaking oral presentations.
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: “The compelling data being presented at IDWeek reflect our scientific advances across infectious diseases in response to the COVID-19 pandemic and surges in respiratory syncytial virus cases. Our PROVENT Phase III data demonstrate AZD7442 may offer much-needed protection for vulnerable populations who may not mount an adequate immune response to COVID-19 vaccination.”
Advancing COVID-19 prevention with cutting-edge science
High-level efficacy and safety data from the PROVENT Phase III trial investigating AZD7442 for prevention of COVID-19 will be presented for the first time following the initial announcement in August. The data showed that AZD7442 compared to placebo achieved a statistically significant reduction in the risk of developing symptomatic COVID-19 prior to virus exposure (pre-exposure prophylaxis).1 More than 75% of participants in the trial had co-morbidities, which includes those with a reduced immune response to vaccination.1 In PROVENT, the LAAB was well tolerated and preliminary analyses show adverse events were balanced between the placebo and AZD7442 groups.
A late-breaker oral presentation of Phase III results will show whether Vaxzevria prevents asymptomatic cases of COVID-19, as well as its capability to shorten viral shedding in breakthrough infections. Understanding the duration of viral shedding may help the implementation of effective public health efforts to control the spread of the virus.2
Late breaking data on nirsevimab
The MELODY Phase III trial data for nirsevimab, an investigational long-acting antibody being developed by AstraZeneca and Sanofi, will demonstrate the potential of nirsevimab to help protect all infants entering their first RSV season with a single dose.